BRPI0416755A - uso de inibidores de catepsina k para o tratamento de doenças de perda óssea severa - Google Patents

uso de inibidores de catepsina k para o tratamento de doenças de perda óssea severa

Info

Publication number
BRPI0416755A
BRPI0416755A BRPI0416755-4A BRPI0416755A BRPI0416755A BR PI0416755 A BRPI0416755 A BR PI0416755A BR PI0416755 A BRPI0416755 A BR PI0416755A BR PI0416755 A BRPI0416755 A BR PI0416755A
Authority
BR
Brazil
Prior art keywords
inhibitors
cathepsin
treatment
bone loss
loss diseases
Prior art date
Application number
BRPI0416755-4A
Other languages
English (en)
Inventor
Martin Missbach
Rainer Gamse
Ulrich Trechsel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0416755A publication Critical patent/BRPI0416755A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"USO DE INIBIDORES DE CATEPSINA K PARA O TRATAMENTO DE DOENçAS DE PERDA óSSEA SEVERA". Esta invenção refere-se em geral a inibidores de catepsina K e seu uso em crescimento ósseo. Especificamente, a invenção refere-se ao uso de inibidores de catepsina K para estimular nova formação óssea em pacientes que necessitam da mesma.
BRPI0416755-4A 2003-11-19 2004-04-19 uso de inibidores de catepsina k para o tratamento de doenças de perda óssea severa BRPI0416755A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03026430 2003-11-19
PCT/EP2004/004155 WO2005049028A1 (en) 2003-11-19 2004-04-19 Use of cathepsin k inhibitors in severe bone loss diseases

Publications (1)

Publication Number Publication Date
BRPI0416755A true BRPI0416755A (pt) 2007-02-27

Family

ID=34610055

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416755-4A BRPI0416755A (pt) 2003-11-19 2004-04-19 uso de inibidores de catepsina k para o tratamento de doenças de perda óssea severa

Country Status (16)

Country Link
US (1) US20070135448A1 (pt)
EP (1) EP1686995A1 (pt)
JP (1) JP2007511548A (pt)
KR (1) KR20060107792A (pt)
CN (1) CN1882343A (pt)
AU (1) AU2004290874A1 (pt)
BR (1) BRPI0416755A (pt)
CA (1) CA2545723A1 (pt)
IL (1) IL175436A0 (pt)
IS (1) IS8498A (pt)
MA (1) MA28174A1 (pt)
MX (1) MXPA06005635A (pt)
NO (1) NO20062870L (pt)
TN (1) TNSN06147A1 (pt)
TW (1) TW200526198A (pt)
WO (1) WO2005049028A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0427380D0 (en) * 2004-12-14 2005-01-19 Novartis Ag Organic compounds
US20080076723A1 (en) * 2006-09-27 2008-03-27 Sylvan Pharmaceuticals Pty Ltd. Inhibition of cathepsin K activity and the treatment and prevention of disease
AU2008221036B2 (en) * 2007-02-28 2014-03-20 Sanofi Imaging probes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9723407D0 (en) * 1997-11-05 1998-01-07 Ciba Geigy Ag Organic compounds
ID24931A (id) * 1997-11-05 2000-08-31 Novartis Ag Dipeptida nitril
JP3892187B2 (ja) * 1998-11-12 2007-03-14 生化学工業株式会社 環状アミド誘導体
GB0003111D0 (en) * 2000-02-10 2000-03-29 Novartis Ag Organic compounds
AR036375A1 (es) * 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
MXPA06000790A (es) * 2003-07-21 2006-04-07 Novartis Ag Combinaciones de un inhibidor de catepsina k y un bisfofonato en el tratamiento de metastasis osea, crecimiento de tumor y perdida osea inducida por tumor.

Also Published As

Publication number Publication date
AU2004290874A1 (en) 2005-06-02
MA28174A1 (fr) 2006-09-01
NO20062870L (no) 2006-08-18
JP2007511548A (ja) 2007-05-10
IS8498A (is) 2006-06-06
TW200526198A (en) 2005-08-16
TNSN06147A1 (en) 2007-11-15
EP1686995A1 (en) 2006-08-09
CN1882343A (zh) 2006-12-20
CA2545723A1 (en) 2005-06-02
KR20060107792A (ko) 2006-10-16
IL175436A0 (en) 2008-04-13
WO2005049028A1 (en) 2005-06-02
MXPA06005635A (es) 2006-08-17
US20070135448A1 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
BR0308663A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas
EE200400020A (et) Asendatud oksasolidinoonid kombineeritud raviks
ECSP056210A (es) Preparación y uso de derivados de alquilarilo para el tratamiento de la obesidad
MEP42808A (en) Use of flibanserin in the treatment of sexual disorders
NO2014010I1 (no) Radium 223 salt slik som Radium 223 diklorid
BR0205722A (pt) Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor
CY1112184T1 (el) Πυριδοξαμινη για χρηση στην αγωγη της διαβητικης nεφροπαθειας στο διαβητη τυπου ii
BR0111591A (pt) Compostos, composição farmacêutica, e, métodos para elevar o nìvel de plasma do hormÈnio de crescimento em um mamìfero, para o tratamento de deficiência da secreção do hormÈnio de crescimento, para o tratamento do retardo do crescimento em crianças, para o tratamento de distúrbios metabólicos associados com a deficiência da secreção do hormÈnio de crescimento, em particular em pacientes idosos, e para promover a cura de ferimentos, recupeção de cirurgia ou recuperação de doenças debilitantes
BRPI0514390A (pt) enanciÈmero de um composto ou um sal farmacêuticamente aceitável ou um éster hidrolisável in vivo do mesmo, uso do mesmo, métodos para o tratamento de cáncer, para produzir um efeito inibidor de eg5 em um animal de sangue quente e para tratar doenças, e, composição farmacêutica
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
BRPI0409359A (pt) análogos quiméricos de somatostatina-dopamina
SE0300098D0 (sv) Use of cyclin D1 inhibitors
CY1105317T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
BR0313081A (pt) Combinação de um inibidor de aromatase com um bisfosfanato
GB0020504D0 (en) Therapeutic method
BR0312929A (pt) Uso de um composto, e, métodos de tratamento, prevenção ou alìvio de uma doença, distúrbio ou condição de um corpo de animal vivo, e da degeneração macular relacionada com a idade de um corpo de animal vivo
BR0309878A (pt) Heterotriciclil-6-alquilideno-penemas como inibidores de beta-lactamase
BRPI0416755A (pt) uso de inibidores de catepsina k para o tratamento de doenças de perda óssea severa
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ME00489B (me) NOVA SINERGIČKA KOMBINACIJA KOJA UKLJUČUJE ROFLUMILAST l FERMOTEROL
HUP0301276A2 (hu) Kombinációs terápia ösztrogénérzékeny betegségek kezelésére
SI1596879T1 (sl) Uporaba spojine kahalalida za pripravo zdravila za zdravljenje luskavice
PL367707A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
ECSP034632A (es) Uso de compuestos del 6-dimetilaminometil-1-fenil-ciclohexaco sustituido en la terapia de la incontinencia urinaria
IL174134A0 (en) Use of a protein in the preparation of a medicament for treatment of fibrotic diseases

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.